News Sentiment

DRTS sentiment intelligence

Alpha Tau Medical Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.55 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.6% over one week, +38.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.6% Price confirming higher
Trend fit Trend active 38.5% over four weeks
Fair value 232.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 39
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
Market source 6
Investing.com 5
TradingView 5
GlobeNewswire 4
Simply Wall Street 3
simplywall.st 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 15
Analyst action 4
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Seeking Alpha Direct company coverage

Alpha Tau rises on Alpha DaRT head and neck cancer data

Alpha Tau Medical (DRTS) stock rose approximately 5% in premarket trading after releasing new data on its Alpha DaRT therapy combined with Merck's Keytruda. The combination demonstrated a 100% objective response rate in nine evaluable head and neck cancer patients. This positive

Tone
Positive 78/100
Event
Market update
Published
21 Jul 2026 13:11
Source
Seeking Alpha
Investing.com Direct company coverage

Alpha Tau reports positive trial results for cancer therapy combo

Alpha Tau Medical Ltd. announced positive results from a clinical study combining its Alpha DaRT therapy with pembrolizumab for elderly patients with head and neck squamous cell carcinoma. The study showed a 100% objective response rate and a median overall survival of 18.2 month

Tone
Positive 75/100
Event
Earnings
Published
21 Jul 2026 13:11
Source
Investing.com
Stock Titan Direct company coverage

All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial

Alpha Tau (Nasdaq: DRTS) announced positive clinical trial results for its Alpha DaRT® therapy combined with pembrolizumab in elderly patients with advanced head and neck cancer, achieving a 100% objective response rate among all 9 evaluable patients. The study reported a median

Tone
Positive 72/100
Event
Earnings
Published
21 Jul 2026 12:11
Source
Stock Titan
Stock Titan Direct company coverage

100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS)

Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT® therapy combined with pembrolizumab in elderly head and neck cancer patients, achieving a 100% objective response rate in nine evaluable patients. The study showed favorable median overall survival of 18.2

Tone
Positive 71/100
Event
Market update
Published
21 Jul 2026 12:11
Source
Stock Titan
Simply Wall Street Direct company coverage

Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued?

Alpha Tau Medical (DRTS) recently reported a significant milestone in its ADMIRE clinical study, successfully treating an immunocompromised patient with recurrent cutaneous squamous cell carcinoma using Alpha DaRT. This news has coincided with a substantial increase in its share

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 22:10
Source
Simply Wall Street
Investing.com Direct company coverage

H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment

H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alpha Tau Medical (NASDAQ:DRTS) after the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in the ADMIRE study. This treatment utilized Alpha DaRT

Tone
Positive 72/100
Event
Analyst action
Published
18 Jul 2026 05:40
Source
Investing.com
Simply Wall Street Direct company coverage

Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT

Alpha Tau Medical's stock rose 6.6% after successfully treating the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE trial. This development expands the potential market for the Alpha DaRT platform

Tone
Positive 70/100
Event
Market update
Published
18 Jul 2026 05:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Alpha Tau Medical (Nasdaq: DRTS) treats first ADMIRE trial patient with Alpha DaRT

Alpha Tau Medical (Nasdaq: DRTS) has announced the successful treatment of the first patient in its ADMIRE clinical trial. This study is evaluating the Alpha DaRT therapy for immunocompromised patients suffering from recurrent cutaneous squamous cell carcinoma (cSCC), a populatio

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 12:41
Source
Stock Titan
Stock Titan Direct company coverage

Alpha Tau Medical (DRTS) CFO trades 2,270 shares in exercise and sale

Alpha Tau Medical's CFO, Levy Raphi, reported exercising 2,270 shares at $2.98 each and simultaneously selling the same number of shares in an open-market transaction at $14.0011 per share. Following these transactions, the CFO directly holds 90,180 Ordinary Shares. This activity

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:43
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS

This article focuses on the enterprise value to revenue forward for Alpha Tau Medical Ltd. (NASDAQ: DRTS). It appears to be a financial data presentation rather than an analytical piece, originating from TradingView and referencing financial data providers like ICE Data Services

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 07:43
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Alpha Tau Medical Ltd. – BOATS:DRTS

This article provides a brief snapshot of the "Price to sales forward" metric for Alpha Tau Medical Ltd. (DRTS) on the BOATS platform. It highlights that no trades were recorded and presents the general financial overview section for the company. The content includes standard fin

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:43
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS)

Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 17,873 shares of DRTS on July 2, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend over the past year with no insider buys and six insider sells for Alpha Tau Medical Ltd. The company, focu

Tone
Negative 31/100
Event
Market update
Published
06 Jul 2026 20:43
Source
GuruFocus
TradingView Direct company coverage

Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. – BOATS:DRTS

The article focuses on the enterprise value to EBITDA forward of Alpha Tau Medical Ltd. (DRTS). It appears to be a financial data point or metric presented within the TradingView platform for this specific company. The content primarily lists navigation and footer elements rather

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:11
Source
TradingView
Simply Wall Street Direct company coverage

Alpha Tau Medical (DRTS) Is Up 17.9% After First International Alpha DaRT Glioblastoma Procedure – Has The Bull Case Changed?

Alpha Tau Medical's stockrose by 17.9% following the successful first international use of its Alpha DaRT technology for glioblastoma treatment in Jerusalem. While this expands the potential application of Alpha DaRT to hard-to-treat tumors, the article emphasizes that it does no

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 18:11
Source
Simply Wall Street
Stock Titan Direct company coverage

Alpha Tau Medical (DRTS) notice: 20,000 shares from option exercise to be sold

Alpha Tau Medical Ltd. (DRTS) has filed a Form 144 notice for the proposed sale of 20,000 ordinary shares. These shares were acquired on July 6, 2026, through the exercise of employee stock options using cash payment. The filing also details multiple past sales by the same holder

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jul 2026 16:11
Source
Stock Titan
Stock Titan Direct company coverage

Alpha Tau Medical (DRTS) CFO exercises 17,873 options and sells 17,873 shares

Alpha Tau Medical Ltd.'s CFO, Raphi Levy, engaged in an exercise-and-sell transaction on July 2, 2026. He exercised 17,873 Ordinary Shares at $2.98 each and simultaneously sold the same number of shares on the open market for an average price of $13.0027 per share. Following thes

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 15:11
Source
Stock Titan
MSN Direct company coverage

Alpha Tau Medical (DRTS) price target increased by 15.15% to 9.69

This article reports that the price target for Alpha Tau Medical (DRTS) has been increased by 15.15%, raising it to $9.69. No further details about the reasons for this increase or who made the adjustment are provided.

Tone
Positive 77/100
Event
Analyst action
Published
03 Jul 2026 06:10
Source
MSN
Stock Titan Direct company coverage

Alpha Tau Medical (NASDAQ: DRTS) CFO sells 2,127 shares after exercising options

Alpha Tau Medical's Chief Financial Officer, Raphi Levy, sold 2,127 Ordinary Shares in an open-market transaction at an average price of $13.0189 per share. This sale followed the exercise of options for the same number of shares at $2.98 each. After the transaction, Levy directl

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 15:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Alpha Tau Medical Ltd. For: 2 July By Investing.com

This article announces the filing of Form 144 for Alpha Tau Medical Ltd. on July 2. It's a short, informative piece from Investing.com, likely indicating an insider's intent to sell restricted stock. The piece includes market data for various indices, commodities, and stocks.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 10:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Levy Raphi to sell 20,000 Alpha Tau shares (DRTS) via Form 144

Levy Raphi has filed a Form 144 to sell 20,000 Ordinary Shares of Alpha Tau Medical Ltd. (DRTS), acquired through employee stock options. This proposed sale, scheduled for July 1, 2026, follows previous dispositions in June 2026 totaling 57,500 shares. The filing provides details

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 10:39
Source
Stock Titan
TradingView Direct company coverage

Alpha Tau Medical Ltd. Warrant 2022-07.03.27 on Alpha Tau Med Rg-A Financial Disclosures & SEC Filings

This article provides a compilation of financial disclosures and SEC filings for Alpha Tau Medical Ltd. (DRTSW) from 2024 to 2026. It highlights key events such as investor conferences, earnings releases, clinical trial advancements, regulatory milestones, and various financial u

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 08:39
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Raphi Levy Sells 20,000 Shares of Alpha Tau Medica

Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 20,000 shares of Alpha Tau Medical Ltd (DRTS) on June 30, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend for Levy, who has sold a total of 90,000 shares over the past year with no purcha

Tone
Negative 28/100
Event
Market update
Published
01 Jul 2026 15:10
Source
GuruFocus
Stock Titan Direct company coverage

Alpha Tau Medical (DRTS) CFO sells 20,000 shares, retains 90,180

Alpha Tau Medical's Chief Financial Officer, Levy Raphi, sold 20,000 Ordinary Shares in an open-market transaction at an average price of $12.0022 per share. Following this sale, Raphi still directly holds 90,180 Ordinary Shares, indicating a retained significant equity exposure.

Tone
Negative 37/100
Event
Market update
Published
01 Jul 2026 12:10
Source
Stock Titan
Stock Titan Direct company coverage

Insider sells 37,500 shares at Alpha Tau Medical (NASDAQ: DRTS)

An insider at Alpha Tau Medical (NASDAQ: DRTS) has sold a total of 37,500 ordinary shares through two transactions in June 2026, generating proceeds of $167,051.00 and $220,004.00 respectively. These sales were reported via a Form 144 filing, which also noted a prior issuance of

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 15:40
Source
Stock Titan